score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.6393	718.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	5.0	0.4	0.4079	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	MEL-IPI_Pat129-Normal-SM-5X2RI
Putatively Actionable	Guideline	Guideline		Copy Number	MET	Amplification				0.0	0.0		Putatively Actionable	Crizotinib	MET inhibition	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Putatively Actionable	Gefitinib	EGFR inhibition	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0				MET Amplification	0.0	MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--MT-ND1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				COL1A1--MT-ND1 Fusion	0.0	MEL-IPI_Pat129		
Investigate Actionability	Guideline			Rearrangement	COL1A1	Fusion	CHD3--COL1A1			0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf													0				CHD3--COL1A1 Fusion	0.0	MEL-IPI_Pat129		
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Frameshift	p.D19fs	0.3487	238.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0.0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310	0	0.0	0.0	0.0	PTEN p.D19fs (Frameshift)	1.0	MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	MEL-IPI_Pat129-Normal-SM-5X2RI
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.D545N	0.7170000000000001	106.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	0.0	0.0	0.0	AR p.D545N (Missense)		MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	MEL-IPI_Pat129-Normal-SM-5X2RI
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat129		
Investigate Actionability	Preclinical			Copy Number	FGFR2	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR2 Deletion		MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	
Biologically Relevant				Rearrangement	NFE2L2	Fusion	NFE2L2--RP11-112J1.1			0.0	0.0																					0				NFE2L2--RP11-112J1.1 Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	MLH3	Fusion	MLH3--HDGF			0.0	0.0																					0				MLH3--HDGF Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	CTNNB1--CARS			0.0	0.0																					0				CTNNB1--CARS Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	NFE2L2	Fusion	TAB2--NFE2L2			0.0	0.0																					0				TAB2--NFE2L2 Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	MTOR	Fusion	RAC1P2--MTOR			0.0	0.0																					0				RAC1P2--MTOR Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	IDH1	Fusion	MT-RNR2--IDH1			0.0	0.0																					0				MT-RNR2--IDH1 Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	PRPF8	Fusion	FMNL3--PRPF8			0.0	0.0																					0				FMNL3--PRPF8 Fusion		MEL-IPI_Pat129		
Biologically Relevant				Rearrangement	CDK4	Fusion	ARID4A--CDK4			0.0	0.0																					0				ARID4A--CDK4 Fusion		MEL-IPI_Pat129		
Biologically Relevant				Copy Number	POT1	Amplification				0.0	0.0																					0				POT1 Amplification		MEL-IPI_Pat129	MEL-IPI_Pat129-Tumor-SM-5X2R7	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat129		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.318																									0				COSMIC Signature (version 2) 1 (32%)		MEL-IPI_Pat129		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.562																									0				COSMIC Signature (version 2) 7 (56%)		MEL-IPI_Pat129		
